产品
编 号：F516581
分子式：C75H108N20O13
分子量：1497.79
分子式：C75H108N20O13
分子量：1497.79
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 91224-37-2
产品详情
生物活性：
Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation.
体内研究：
Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals.Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNAlevels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β.Animal Model:Female, 8-week-old C57BL/6 (B6) and BALB/c mice.
Dosage:36 μg/mouse.
Administration:IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection).
Result:At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice.Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi.Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi.Significantly reduced the level of IL-18 mRNA at 1 day pi.
Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation.
体内研究：
Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals.Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNAlevels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β.Animal Model:Female, 8-week-old C57BL/6 (B6) and BALB/c mice.
Dosage:36 μg/mouse.
Administration:IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection).
Result:At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice.Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi.Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi.Significantly reduced the level of IL-18 mRNA at 1 day pi.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备